🧬 Biology & Life Sciences

A Mendelian randomization study confirms that gut microbiota causally modify brain structure in psychiatric disorders, with brain structure fully mediating the microbiome's effect in bipolar disorder and anorexia nervosa.

A critical review in npj Aging asks whether epigenetic aging clocks are actually necessary, examining the superiority of second-generation clocks for mortality prediction alongside concerns about demographic biases and clinical utility.

A comprehensive review in Advanced Science examines how to balance cell growth and product synthesis in microbial cell factories, analyzing 235 high-value chemicals through genome-scale metabolic models and membrane-less organelles.

GLP-1 receptor agonists act far beyond appetite suppression—confirmed protective effects on heart, kidney, and liver are expanding the therapeutic rationale, while the first non-peptide oral formulation (orforglipron) and dual/triple agonists broaden access and efficacy.

CRISPR gene editing is addressing core limitations of CAR-T cell therapy — T-cell exhaustion, immune checkpoint evasion, and the cost barrier of autologous manufacturing — through immune checkpoint knockout, base-edited allogeneic products, and multi-target engineering for hematological malignancies.

Epigenetic clocks can predict mortality and disease risk in research cohorts, but clinical adoption faces barriers of cost, standardization, interpretability, and the absence of actionable thresholds — a gap between statistical association and medical utility that the field is only beginning to address.

Organ-on-chip platforms and microphysiological systems are moving from academic curiosities to regulatory-recognized tools for drug screening, driven by the FDA Modernization Act 2.0 and mounting evidence that human-tissue-based systems predict drug toxicity more accurately than animal models.

Misfolded alpha-synuclein may travel from the gut to the brain via the vagus nerve years before Parkinson's motor symptoms appear. A 2024 Neuron paper shows gut-injected α-synuclein triggers both Parkinson's and Alzheimer's co-pathology—challenging the view that these are distinct diseases.

Your chronological age counts birthdays. Your biological age counts methylation marks on DNA. Epigenetic clocks now predict disease risk and mortality better than any single biomarker—and a randomized trial shows vitamin D + omega-3 + exercise can slow them. But which clock should we trust?

In July 2019, Victoria Gray became the first sickle cell patient to receive CRISPR therapy. By December 2023, Casgevy had FDA approval. The CLIMB SCD-121 final results now show 91% of patients free of vaso-occlusive crises—but at $2.2 million per treatment, the equity question looms large.

Stem cells can now self-organize into structures that recapitulate key events of early embryo development—without sperm, egg, or uterus. These 'synthetic embryo models' are transforming developmental biology while forcing a reckoning with the definition of 'embryo' itself.

Single-cell RNA sequencing revolutionised biology by revealing the transcriptomic identity of individual cells, but it requires dissociating tissues into cell suspensions — destroying the spatial cont...

The human genome encodes thousands of long non-coding RNAs (lncRNAs) — transcripts longer than 200 nucleotides that do not encode proteins. Once dismissed as transcriptional noise, lncRNAs are now rec...

Neurological diseases — Alzheimer's, Parkinson's, schizophrenia — are notoriously difficult to study because the human brain is inaccessible during life and animal models poorly recapitulate human-spe...

Classical CRISPR-Cas9 corrects genes by cutting both DNA strands, relying on the cell's repair machinery to fix the break — a process that is inherently imprecise and produces unwanted insertions and ...

The human gut harbours trillions of microorganisms that produce thousands of metabolites — short-chain fatty acids, bile acid derivatives, tryptophan catabolites, neurotransmitter precursors — which c...

Genomics tells us what a cell *could* do; proteomics tells us what it *is* doing. Proteins are the functional molecules of life — enzymes, receptors, structural components, signalling molecules — and ...

Every cell in the human body contains a molecular clock — interlocking transcription-translation feedback loops involving CLOCK, BMAL1, PER, and CRY genes that oscillate with ~24-hour periodicity. The...

The human genome contains ~20,000 protein-coding genes, yet the proteome comprises over 100,000 distinct proteins. Alternative splicing (AS) — the process by which different exon combinations are incl...

Telomeres — repetitive TTAGGG sequences at chromosome ends — shorten with each cell division because DNA polymerase cannot fully replicate linear chromosome termini. When telomeres reach a critical le...

Autophagy — literally "self-eating" — is the process by which cells engulf and degrade their own components through lysosomes. It serves as a quality control mechanism: removing damaged mitochondria, ...

Ferroptosis — a form of regulated cell death driven by iron-dependent lipid peroxidation — was named in 2012 by Brent Stockwell's group. Unlike apoptosis (programmed, caspase-dependent, immunologicall...

Liquid biopsy — detecting cancer biomarkers in blood and other body fluids — promises to replace invasive tissue biopsies with a simple blood draw. While circulating tumour DNA (ctDNA) has received th...

Single-cell RNA sequencing revolutionised our understanding of cellular heterogeneity, but gene expression is only one layer of cellular identity. Chromatin accessibility (ATAC-seq), DNA methylation, ...

Malaria killed over 600,000 people in 2022, predominantly children in sub-Saharan Africa. Insecticide-treated nets and indoor residual spraying have reduced transmission but face growing insecticide r...

Bacteriophages — viruses that specifically infect and kill bacteria — were used therapeutically before antibiotics existed. Rediscovered amid the antibiotic resistance crisis, phage therapy offers exq...

RNA interference (RNAi) — silencing specific genes by delivering small interfering RNA (siRNA) — has matured from a laboratory tool to FDA-approved therapeutics. Lin Xiong, Shuang Chen, Sihui Li et al...

CRISPR-Cas systems were developed for genome editing, but a serendipitous property — the "collateral cleavage" activity of Cas12 and Cas13, where target recognition triggers non-specific degradation o...

Synthetic biology aims to engineer living organisms as programmable manufacturing platforms — microbial "cell factories" that convert cheap feedstocks (sugars, CO₂, waste streams) into valuable chemic...

The brain consumes ~20% of the body's energy despite comprising only 2% of body weight. Neurons are extraordinarily dependent on mitochondrial oxidative phosphorylation, making them uniquely vulnerabl...

Traditional CRISPR gene editing cuts DNA to knock out or replace genes—a powerful but permanent and sometimes risky intervention. **Epigenome editing** takes a fundamentally different approach: it use...

Antimicrobial resistance (AMR) kills **1.27 million people annually** and is projected to cause 1.91 million direct AMR deaths annually by 2050 (GRAM 2024, Lancet), though earlier O'Neill Commission e...

Enzymes catalyze reactions with exquisite selectivity under mild conditions—but natural enzymes rarely perform well in industrial settings (high temperatures, organic solvents, extreme pH). **Directed...

Drug development fails 90% of the time in clinical trials, largely because animal models and 2D cell cultures poorly predict human responses. **Organoids**—self-organizing 3D structures grown from ste...

COVID-19 mRNA vaccines proved that RNA therapeutics work at global scale. But vaccines are just the beginning. The same lipid nanoparticle (LNP) delivery platform can carry siRNA to silence disease ge...

Traditional biotechnology requires growing living cells—slow, expensive, and constrained by cellular survival needs. **Cell-free protein synthesis (CFPS)** extracts the transcription-translation machi...

Aging is the single largest risk factor for cancer, cardiovascular disease, neurodegeneration, and diabetes—conditions that collectively account for >70% of deaths in developed countries. The discover...

Spatial transcriptomics has long required sequencing to read gene expression in tissue. RAEFISH demonstrates that imaging alone can detect all 23,000 human genes at single-molecule resolution—no sequencer needed.

RFdiffusion3 from the Institute for Protein Design at UW enables de novo design of all-atom biomolecular interactions, operating approximately 10x faster than its predecessor and outperforming on 37 of 41 enzyme scaffold benchmarks by inverting AlphaFold3's prediction framework into a generative model.

PM359 has produced the first-ever clinical results for prime editing therapy: NADPH oxidase activity was restored in 58% of neutrophils by Day 15 and 66% by Day 30 in a patient with chronic granulomatous disease, achieved without the double-strand DNA breaks that characterize CRISPR-Cas9 approaches.

Fecal microbiota transplantation works against C. difficile, but the field lost its main stool bank in 2024. This study shows a single proline-fermenting engineered strain can achieve the same protective effect—raising the question of whether designer microbiomes can replace donor-dependent therapies.

Brain organoids have transformed neuroscience, but they die from the inside out—their centers become necrotic because no blood vessels deliver oxygen to the core. This study integrates endothelial networks into cerebral organoids using ECM-based hydrogel droplets, creating functional neurovascular units that keep the interior alive.

The human Ensemble Cell Atlas v2.0 assembles 10.8 million scRNA-seq cells and 1.45 million scATAC-seq profiles across 42 human tissues under a unified annotation framework, designed explicitly for training AI foundation models like scMulan.

A heart-on-chip microphysiological system now enables rapid screening of lipid nanoparticle-mRNA formulations for cardiac delivery, predicting in vivo transfection efficacy. This platform addresses a critical bottleneck in developing mRNA therapeutics for heart disease.

More than half of rare disease patients remain undiagnosed after standard short-read sequencing. Two 2025 studies demonstrate that long-read sequencing detects structural variants, repeat expansions, and epigenetic modifications invisible to conventional methods, solving 12-17% of previously intractable cases.